FUSE-AI @ Swiss Congress of Radiology 2025 – Feedback, Exchange and New Perspectives
Reference: Home. SGR-SSR Congress, https://congress.sgr-ssr.ch/, accessed 26 May 2025.
The Swiss Congress of Radiology (SCR) 2025 once again proved to be a key meeting point for innovation, exchange, and collaboration in European medical imaging – and FUSE-AI was proud to be part of it.
From May 15–17 2025, our team, represented by Oliver Gessl (Co-CEO), Juri Rohde (COO, Head of Q&RA) and Antonia Klobe (Product Manager), was on site to engage in high-level dialogue with our Swiss reference sites, demonstrate our DICOM connected AI plug-in “Prostate.Carcinoma.ai” integrated in mint Lesion and explore new pathways for collaboration.
Clinical Dialogue: Strengthening Ties with Our Reference Clinics
A core focus of our presence at SCR 2025 was the valuable exchange with existing clinical partners that are currently using or testing our product. Direct conversations with representatives from reference institutions such as the Kantonsspital Aarau and the CHUV Lausanne enabled us to gather in-depth feedback on the use of Prostate.Carcinoma.ai in clinical practice. These insights will directly shape the further development of our solution – ensuring it remains close to user needs and clinical workflows.
Live Demos: How our AI solution supports radiologists within mint Lesion
Together with our integration partner Mint Medical, we presented how Prostate.Carcinoma.ai seamlessly integrates into mint Lesion to support radiologists with AI-assisted prostate cancer MRI interpretation. Through targeted product demonstrations, we were able to reach out to new clinics and decision-makers, highlighting how our AI solution reduces overall MRI prostate analysis time, increases efficiency by minimizing manual work and offers more accurate prostate volumetry.
Lifelong Learning: Insights from Science and Industry
SCR 2025 also offered our team the opportunity to deepen expertise through scientific sessions and industry talks. Current research, regulatory discussions and best practices around AI in radiology provided essential impulses that support our ongoing innovation and product development.
Strategic Expansion: Toward broader PACS and Platform Integration
In parallel, our team held numerous exploratory meetings with vendors of PACS (Picture Archiving and Communication Systems) and other platform providers. The goal: to broaden Prostate.Carcinoma.ai’s technical compatibility and establish new strategic partnerships. We are actively working toward integrating our solution into established PACS environments and joining broader AI marketplaces that are gaining traction in clinical imaging.
Initial technical discussions were held with leading PACS vendors and platform providers. These laid the groundwork for future integrations, discussed DICOM compatibility (e.g. SEG object support), and evaluated potential paths to become part of existing AI platforms. Especially promising were conversations around deployment options and how interest from clinics may accelerate marketplace inclusion.
Our Takeaway
SCR 2025 reinforced our belief: true innovation in radiology happens through collaboration – between clinicians, solution providers, and platform partners. We are excited about the partnerships and initiatives emerging from the congress, and we look forward to further expanding our reach and impact across European radiology.
Stay tuned as we continue to evolve Prostate.Carcinoma.ai, grow our partnerships, and help shape the future of AI in diagnostic imaging.